Your browser doesn't support javascript.
loading
Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine miRNA Transcriptome.
Jeon, Jouhyun; Olkhov-Mitsel, Ekaterina; Xie, Honglei; Yao, Cindy Q; Zhao, Fang; Jahangiri, Sahar; Cuizon, Carmelle; Scarcello, Seville; Jeyapala, Renu; Watson, John D; Fraser, Michael; Ray, Jessica; Commisso, Kristina; Loblaw, Andrew; Fleshner, Neil E; Bristow, Robert G; Downes, Michelle; Vesprini, Danny; Liu, Stanley; Bapat, Bharati; Boutros, Paul C.
Afiliação
  • Jeon J; Ontario Institute for Cancer Research, Toronto, ON, Canada.
  • Olkhov-Mitsel E; Lunenfeld-Tannenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.
  • Xie H; Ontario Institute for Cancer Research, Toronto, ON, Canada.
  • Yao CQ; Ontario Institute for Cancer Research, Toronto, ON, Canada.
  • Zhao F; Lunenfeld-Tannenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.
  • Jahangiri S; Sunnybrook Research Institute and Department of Radiation Oncology, Sunnybrook-Odette Cancer Centre, Toronto, ON, Canada.
  • Cuizon C; Lunenfeld-Tannenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.
  • Scarcello S; Sunnybrook Research Institute and Department of Radiation Oncology, Sunnybrook-Odette Cancer Centre, Toronto, ON, Canada.
  • Jeyapala R; Lunenfeld-Tannenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.
  • Watson JD; Ontario Institute for Cancer Research, Toronto, ON, Canada.
  • Fraser M; Ontario Institute for Cancer Research, Toronto, ON, Canada.
  • Ray J; Sunnybrook Research Institute and Department of Radiation Oncology, Sunnybrook-Odette Cancer Centre, Toronto, ON, Canada.
  • Commisso K; Sunnybrook Research Institute and Department of Radiation Oncology, Sunnybrook-Odette Cancer Centre, Toronto, ON, Canada.
  • Loblaw A; Sunnybrook Research Institute and Department of Radiation Oncology, Sunnybrook-Odette Cancer Centre, Toronto, ON, Canada.
  • Fleshner NE; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Bristow RG; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Downes M; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
  • Vesprini D; Manchester Cancer Research Centre, University of Manchester, Manchester, UK.
  • Liu S; Ontario Institute for Cancer Research, Toronto, ON, Canada.
  • Bapat B; Sunnybrook Research Institute and Department of Radiation Oncology, Sunnybrook-Odette Cancer Centre, Toronto, ON, Canada.
  • Boutros PC; Sunnybrook Research Institute and Department of Radiation Oncology, Sunnybrook-Odette Cancer Centre, Toronto, ON, Canada.
J Natl Cancer Inst ; 112(3): 247-255, 2020 03 01.
Article em En | MEDLINE | ID: mdl-31161221
BACKGROUND: The development of noninvasive tests for the early detection of aggressive prostate tumors is a major unmet clinical need. miRNAs are promising noninvasive biomarkers: they play essential roles in tumorigenesis, are stable under diverse analytical conditions, and can be detected in body fluids. METHODS: We measured the longitudinal stability of 673 miRNAs by collecting serial urine samples from 10 patients with localized prostate cancer. We then measured temporally stable miRNAs in an independent training cohort (n = 99) and created a biomarker predictive of Gleason grade using machine-learning techniques. Finally, we validated this biomarker in an independent validation cohort (n = 40). RESULTS: We found that each individual has a specific urine miRNA fingerprint. These fingerprints are temporally stable and associated with specific biological functions. We identified seven miRNAs that were stable over time within individual patients and integrated them with machine-learning techniques to create a novel biomarker for prostate cancer that overcomes interindividual variability. Our urine biomarker robustly identified high-risk patients and achieved similar accuracy as tissue-based prognostic markers (area under the receiver operating characteristic = 0.72, 95% confidence interval = 0.69 to 0.76 in the training cohort, and area under the receiver operating characteristic curve = 0.74, 95% confidence interval = 0.55 to 0.92 in the validation cohort). CONCLUSIONS: These data highlight the importance of quantifying intra- and intertumoral heterogeneity in biomarker development. This noninvasive biomarker may usefully supplement invasive or expensive radiologic- and tissue-based assays.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / MicroRNAs Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans / Male Idioma: En Revista: J Natl Cancer Inst Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / MicroRNAs Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Humans / Male Idioma: En Revista: J Natl Cancer Inst Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá